Skip to main content
Bacil Pharma Ltd. logo

Bacil Pharma Ltd. — Investor Relations & Filings

Ticker · 524516 ISIN · INE711D01018 BSE.NS Manufacturing
Open in API
Filings indexed 5 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country IN India
Listing BSE.NS 524516

About Bacil Pharma Ltd.

https://bacilpharma.co.in/

Bacil Pharma Ltd. specializes in the development, production, and distribution of a broad spectrum of pharmaceutical formulations. The company’s core activities involve the manufacturing of generic medicines across multiple therapeutic categories, including anti-infectives, antibiotics, analgesics, and anti-inflammatory agents. Its product range includes solid dosage forms such as tablets and capsules, as well as liquid oral preparations. Bacil Pharma Ltd. focuses on maintaining rigorous quality assurance protocols and manufacturing standards to deliver reliable healthcare products. The organization aims to provide accessible therapeutic solutions through a structured supply chain, catering to diverse clinical requirements and patient populations.

Recent filings

Filing Released Lang Actions
Company has not entered any Related Party Transactions during the half year ended 31st March, 2026
Regulatory Filings Classification · 98% confidence The document is a short notification addressed to the stock exchange under SEBI LODR Regulation 23(9) disclosing that there were no Related Party Transactions for the quarter/half-year ended March 31, 2026. It does not contain financial statements or serve as a report itself but is a statutory disclosure to the regulator. This falls under general regulatory filings that do not fit other categories.
2026-05-22 English
Statement of Deviation or Variation in ultilization of Funds under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the ....
Regulatory Filings Classification · 85% confidence The document is a compliance announcement submitted to the stock exchange under SEBI Listing Obligations (Regulation 32) confirming no fund‐raising occurred. It contains no substantive financial statements or actual financing details, nor is it a formal financial report. This is a regulatory filing/disclosure rather than a capital report or financial report, so it falls under the generic Regulatory Filings category (RNS).
2026-05-22 English
Audited Financial Results for 31st March, 2026
Interim / Quarterly Report Classification · 90% confidence The document is the official stock-exchange filing under SEBI LODR Regulations 30 and 33, showing the Board’s approval of the audited financial results for the quarter and year ended March 31, 2026, and then reproducing full financial statements (Balance Sheet, Cash Flow Statement, Statement of Profit & Loss with quarter and year columns), notes, and the independent auditor’s report. It is not merely a high-level earnings summary (ER), nor a full Annual Report (10-K) with narrative sections, nor just an auditor’s certification (RNS). It is a comprehensive quarterly/interim financial report containing substantive financial data for a period shorter than a full fiscal year. Therefore, it falls under Interim / Quarterly Report (Code: IR). FY 2026
2026-05-22 English
Outcome of Board Meeting for Audited Results for 31st March, 2026
Interim / Quarterly Report Classification · 85% confidence The document is a SEBI LODR Reg. 30/33 compliant disclosure entitled “Outcome of Board Meeting” that includes fully audited financial statements (Balance Sheet, Cash Flow, Profit & Loss) for the quarter and year ended March 31, 2026, along with the Independent Auditor’s Report. This is more than a brief earnings release and contains full financial statements for a quarter (and year‐end), but it is not a full Annual Report (10-K) with narrative, governance, and MD&A. It is therefore a comprehensive periodic financial report (interim/quarterly report). FY 2026
2026-05-22 English
Bacil Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2026 ,inter alia, to consider and approve Intimation of Board Meeting to ....
Regulatory Filings Classification · 85% confidence The document is a formal SEBI LODR Regulation 29(1) notice to the stock exchange informing of a forthcoming Board of Directors meeting date. It does not announce any board or management changes, nor does it include financial results itself, nor is it a report publication announcement. It is a regulatory compliance disclosure, fitting the general “Regulatory Filings” category.
2026-05-11 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.